Aleph-4

Last updated
Aleph-4
Aleph-4 v2.svg
Clinical data
Other namesALEPH-4; 4-Isopropylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-isopropylthioamphetamine; 4-iPrS-DMA
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action 12–20 hours [1]
Identifiers
  • 1-(2,5-dimethoxy-4-propan-2-ylsulfanylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H23NO2S
Molar mass 269.40 g·mol−1
3D model (JSmol)
  • CC(C)SC1=C(C=C(C(=C1)OC)CC(C)N)OC
  • InChI=1S/C14H23NO2S/c1-9(2)18-14-8-12(16-4)11(6-10(3)15)7-13(14)17-5/h7-10H,6,15H2,1-5H3
  • Key:BCWCXWKCQMBFBQ-UHFFFAOYSA-N

Aleph-4, or ALEPH-4, also known as 4-isopropylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. [1] It is one of the Aleph series of compounds. [1] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-4's dose as 7 to 12 mg orally and its duration as 12 to 20 hours. [1] The effects of Aleph-4 have been reported to include closed-eye imagery, enhanced visual appreciation, emotional changes, and physical side effects and toxicity indications, among others. [1] One of the reports remarked that it was "one of the most profound and deep learning experiences" they had had. [1] However, Shulgin was unwilling to push the dose higher than 12 mg due to toxicity concerns. [1] The chemical synthesis of Aleph-4 has been described. [1] Aleph-4 was first described in the scientific literature by Shulgin, David E. Nichols, Peyton Jacob III, and other colleagues in 1978. [2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991. [1] The drug was encountered as a novel designer drug in Japan in 2009. [3] [4]

Contents

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. https://erowid.org/library/books_online/pihkal/pihkal005.shtml
  2. ↑ Braun U, Braun G, Jacob P, Nichols DE, Shulgin AT (1978). "Mescaline Analogs: Substitutions at the 4-Position" (PDF). In Barnett G, Trsic M, Willette RE (eds.). QuaSAR: Quantitative Structure Activity Relationships Of Analgesics, Narcotic Antagonists, And Hallucinogens (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 22. National Institute on Drug Abuse. pp. 27–37. PMID   101882.
  3. ↑ Suzuki, J., Moriyasu, T., Nagashima, M., Kanai, C., Shimizu, M., Hamano, T., & Nagayama, T. (2010). Analysis of uncontrolled drugs purchased in fiscal year 2009. Ann RepTokyo Metrop Inst Public Health [Japanese: Tōkyō-to Kenkō Anzen Kenkyū Sentā Kenkyū Nenpō], 61, 163–172. https://isomerdesign.com/bitnest/external/TokyoMetr.Inst.PH/61.163
  4. ↑ Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y (February 2010). "2008年度買い上げ違法ドラッグ製品から検出された新規流通デザイナードラッグの同定" [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008]. Yakugaku Zasshi (in Japanese). 130 (2): 263–70. doi:10.1248/yakushi.130.263. PMID   20118651.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.